tubulin beta 6 class VGenealiases: FPVEPD · HsT1601 · TUBB-5
Q-omics provides the consensus-scored TUBB6 profile across patient tissues and cancer cell-line models. TUBB6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TUBB6 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, TUBB6 protein abundance shows 30,291 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, KIRC, and PDAC as cancer lineages where TUBB6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBB6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBB6 survival associations across molecular data types. TUBB6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBB6 RNA expression–survival associations across cancer types. High TUBB6 expression shows unfavorable associations in ACC, HNSC, BLCA, KIRC, MESO and OV. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TUBB6 RNA expression.
This table summarizes TUBB6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TUBB6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBB6 shows lower tumor expression in BLCA, LUAD, KICH, BRCA and UCEC and higher tumor expression in KIRC. The KIRC box plot shows higher TUBB6 RNA expression in tumor versus normal tissue (log2 FC = +1.284, t-test p < 0.001).
This table shows molecular features associated with TUBB6 in patient tissues and cancer cell lines. In patient samples, TUBB6 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TUBB6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and SOFT_TISSUE.
